We are live on ! Find out more
TRAW icon

Traws Pharma
TRAW

10 hedge funds and large institutions have $3.46M invested in Traws Pharma in 2016 Q4 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

100% more first-time investments, than exits

New positions opened: 4 | Existing positions closed: 2

25% more funds holding

Funds holding: 8 → 10 (+2)

0% more funds holding in top 10

Funds holding in top 10: 1 → 1 (0)

0% more ownership

Funds ownership: 0% → 0% (+0%)

9% less capital invested

Capital invested by funds: $3.8M → $3.46M (-$340K)

Holders
10
Holders Change
+2
Holders Change %
+25%
% of All Funds
0.25%
Holding in Top 10
1
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
4
Increased
3
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
+$148K
2
Renaissance Technologies
Renaissance Technologies
New York
+$74.2K
3
Vanguard Group
Vanguard Group
Pennsylvania
+$59.4K
4
Citadel Advisors
Citadel Advisors
Florida
+$44.5K
5
VKH
Virtu KCG Holdings
New York
+$29.7K

Top Sellers

Rank Fund Capital Flow
1
EGA
Eagle Global Advisors
Texas
-$44K
2
AIM
Alambic Investment Management
California
-$36K
3
TRCT
Tower Research Capital (TRC)
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
TCP
1
Tyndall Capital Partners
New York
$1.18M – – –
SM
2
Sabby Management
Florida
$1.03M +$148K +10 +14%
BC
3
Boxer Capital
California
$718K – – –
Renaissance Technologies
4
Renaissance Technologies
New York
$279K +$74.2K +5 +29%
Vanguard Group
5
Vanguard Group
Pennsylvania
$103K +$59.4K +4 +100%
WMSA
6
Weiss Multi-Strategy Advisers
New York
$55K – – –
Citadel Advisors
7
Citadel Advisors
Florida
$41K +$44.5K +3 New
VKH
8
Virtu KCG Holdings
New York
$25K +$29.7K +2 New
AIM
9
Acrospire Investment Management
Illinois
$10K +$14.8K +1 New
UBS Group
10
UBS Group
Switzerland
$7K +$14.8K +1 New
Morgan Stanley
11
Morgan Stanley
New York
$3K – – –
HFM
12
Hartford Financial Management
Connecticut
$2K – – –
BFA
13
BlackRock Fund Advisors
California
$1K – – –
Citigroup
14
Citigroup
New York
$1K – – –
Creative Planning
15
Creative Planning
Kansas
$1K – – –
EGA
16
Eagle Global Advisors
Texas
– -$44K -3 Closed
AIM
17
Alambic Investment Management
California
– -$36K -2 Closed
TRCT
18
Tower Research Capital (TRC)
New York
– -$1K – –

TRAW Hedge Fund Activity: Q4 2016 in Review

10 of the 4,000 institutional investors tracked by Wall St. Rank reported a position in Traws Pharma (TRAW) for Q4 2016, worth a combined $3.46M — down 9% from $3.8M a quarter earlier.

Buyers outnumbered sellers: 4 funds opened new TRAW positions and 2 closed out — a net gain of 2 holders — while 3 added to existing stakes and 0 trimmed.

The largest buyer was Sabby Management, adding an estimated $148K. The largest seller was Eagle Global Advisors, exiting entirely with an estimated $44K sold.

  • 10 institutional investors held Traws Pharma (TRAW) as of Q4 2016, up from 8 in Q3 2016.
  • Funds reported $3.46M of Traws Pharma stock for Q4 2016, down 9% quarter-over-quarter.
  • 4 funds opened new Traws Pharma positions in Q4 2016 and 2 closed out, a net change of +2 holders.
  • The largest Traws Pharma buyer in Q4 2016 was Sabby Management, an estimated $148K added.
  • The largest Traws Pharma seller in Q4 2016 was Eagle Global Advisors, an estimated $44K sold.

Based on aggregated 13F filings for Q4 2016.